Valuation: Vertex Pharmaceuticals Incorporated

Market Cap 13TCr 12TCr 11TCr 10TCr 19TCr 12,76100Cr 19TCr 1,29300Cr 50TCr 6,27200Cr 50TCr 49TCr 21,61500Cr P/E 2026 *
30.2x
P/E 2027 * 26.8x
Enterprise Value 12TCr 11TCr 9.74TCr 9.08TCr 17TCr 11,54300Cr 17TCr 1,16900Cr 45TCr 5,67400Cr 46TCr 45TCr 19,55300Cr EV / Sales 2026 *
9.3x
EV / Sales 2027 * 8.19x
Free-Float
99.8%
Yield 2026 *
-
Yield 2027 * -
1 day+6.03%
1 week+7.47%
Current month+6.30%
1 month+23.28%
3 months+20.36%
6 months+16.79%
Current year+16.47%
1 week 487.62
Extreme 487.62
529.14
1 month 433.8
Extreme 433.8
529.14
Current year 412.27
Extreme 412.27
529.14
1 year 362.5
Extreme 362.5
529.14
3 years 335.82
Extreme 335.82
529.14
5 years 176.36
Extreme 176.36
529.14
10 years 71.46
Extreme 71.46
529.14
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2020
Director of Finance/CFO 58 10/04/2019
Chief Tech/Sci/R&D Officer - 01/07/2021
Director TitleAgeSince
Director/Board Member 66 01/01/1998
Chairman 70 01/05/2012
Director/Board Member 57 18/06/2015
Date Insider Type Main position Quantity % Market Cap.
26/06Sell

Chief Technology Officer

-596 0.0002%
18/06Sell

Chief Technology Officer

-1,020 0.0004%
15/06Sell

Chief Technology Officer

-4,062 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+6.03%+7.47%+14.89%+51.92% 13TCr
+1.86%+0.48%+55.50%+163.08% 1,08200Cr
+3.57%+3.29%+68.60%+61.03% 63TCr
+3.99%+3.05%+37.93%+93.37% 46TCr
+3.86%+1.64%+32.57%+24.89% 34TCr
-0.56%+0.96%+41.67%+39.35% 30TCr
-0.08%+1.30%+32.15%+44.48% 29TCr
-1.54%+2.81%-25.35%-39.61% 22TCr
+3.55%+4.41%+25.45%+66.28% 20TCr
+4.21%+2.65%+17.47%+71.11% 16TCr
Average +2.49%+5.12%+30.09%+57.59% 38.26TCr
Weighted average by Cap. +2.38%+5.69%+41.35%+82.21%

Financials

2026 *2027 *
Net sales 1.3TCr 1.14TCr 1.05TCr 976.33Cr 1.85TCr 1,24100Cr 1.88TCr 13TCr 4.89TCr 61TCr 4.89TCr 4.79TCr 2,10300Cr 1.43TCr 1.25TCr 1.15TCr 1.07TCr 2.03TCr 1,35800Cr 2.06TCr 14TCr 5.35TCr 67TCr 5.36TCr 5.24TCr 2,30100Cr
Net income 445.12Cr 389.13Cr 357.61Cr 333.33Cr 632.24Cr 42TCr 641.82Cr 4.29TCr 1.67TCr 21TCr 1.67TCr 1.63TCr 72TCr 505.3Cr 441.73Cr 405.95Cr 378.39Cr 717.71Cr 48TCr 728.59Cr 4.87TCr 1.89TCr 24TCr 1.9TCr 1.86TCr 81TCr
Net Debt -1.28TCr -1.12TCr -1.03TCr -957.37Cr -1.82TCr -1,21700Cr -1.84TCr -12TCr -4.79TCr -60TCr -4.8TCr -4.7TCr -2,06200Cr -1.71TCr -1.5TCr -1.38TCr -1.28TCr -2.43TCr -1,63100Cr -2.47TCr -17TCr -6.42TCr -80TCr -6.43TCr -6.29TCr -2,76300Cr
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Employees
6,400
Date Price Change Volume
02/26/02 $528.04 +6.03% 18,55,943
01/26/01 $498.01 +0.26% 14,44,535
30/26/30 $496.73 -0.58% 17,38,335
29/26/29 $499.65 +1.69% 20,55,780
26/26/26 $491.34 +2.32% 86,93,047
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
528.04USD
Average target price
548.69USD
Spread / Average Target
+3.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VRTX Stock